A phase II study of carboplatin and paclitaxel in esophageal cancer

被引:38
作者
El-Rayes, BF [1 ]
Shields, A [1 ]
Zalupski, M [1 ]
Heilbrun, LK [1 ]
Jain, V [1 ]
Terry, D [1 ]
Ferris, A [1 ]
Philip, PA [1 ]
机构
[1] Wayne State Univ, Karmanos Canc Inst, Div Hematol & Oncol, Detroit, MI 48201 USA
关键词
carboplatin; combination chemotherapy; esophageal cancer; paclitaxel;
D O I
10.1093/annonc/mdh230
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with esophageal cancer. Materials and methods: Thirty-five patients were enrolled. Patients were treated with paclitaxel 200 mg/m(2) intravenously (i.v.) over 3 h and carboplatin i.v. at an AUC of 5 mg/h/ml. Thirty-three patients were assessable for toxicity and objective response. Results: A total of 166 treatment courses were administered with a median of five courses per patient. The objective response rate was 43% [90% confidence interval (CI) 0.3-0.58] by the intention-to-treat analysis. The median response duration was 2.8 months (90% Cl 2.1-5.4). The median survival time was 9 months (90% Cl 7-13.8) and the I-year survival rate was 43% (90% Cl 0.29-0.57). The major grade 3-4 toxicity observed was neutropenia, occurring in 17 patients (52%). There were no treatment-related deaths. Conclusions: The combination of carboplatin and paclitaxel is an moderately active and tolerable regimen in advanced esophageal cancer.
引用
收藏
页码:960 / 965
页数:6
相关论文
共 25 条
[1]   ACTIVITY OF TAXOL IN PATIENTS WITH SQUAMOUS-CELL CARCINOMA AND ADENOCARCINOMA OF THE ESOPHAGUS [J].
AJANI, JA ;
ILSON, DH ;
DAUGHERTY, K ;
PAZDUR, R ;
LYNCH, PM ;
KELSEN, DP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (14) :1086-1091
[2]  
ARMANIOS M, 2003, ASCO P CHIC IL AL VA
[3]   Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer [J].
Bleiberg, H ;
Conroy, T ;
Paillot, B ;
Lacave, AJ ;
Blijham, G ;
Jacob, JH ;
Bedenne, L ;
Namer, M ;
DeBesi, P ;
Gay, F ;
Collette, L ;
Sahmoud, T .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) :1216-1220
[4]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[5]  
CASELLA G, 1987, CAN J STAT, V14, P113
[6]  
CREAVEN P, 1995, SEMIN ONCOL, V22, P13
[7]   ONE-SAMPLE MULTIPLE TESTING PROCEDURE FOR PHASE-II CLINICAL-TRIALS [J].
FLEMING, TR .
BIOMETRICS, 1982, 38 (01) :143-151
[8]   COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS [J].
HERSKOVIC, A ;
MARTZ, K ;
ALSARRAF, M ;
LEICHMAN, L ;
BRINDLE, J ;
VAITKEVICIUS, V ;
COOPER, J ;
BYHARDT, R ;
DAVIS, L ;
EMAMI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) :1593-1598
[9]  
IIZUKA T, 1992, JPN J CLIN ONCOL, V22, P172
[10]   Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus [J].
Ilson, DH ;
Ajani, J ;
Bhalla, K ;
Forastiere, A ;
Huang, Y ;
Patel, P ;
Martin, L ;
Donegan, J ;
Pazdur, R ;
Reed, C ;
Kelsen, DP .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1826-1834